Skip to content

Study · Observational study · 2025

3 results

GLP-1 Agonists in Aesthetic Surgery: Implications for Perioperative Outcomes and Body Contouring Procedures.

Albanese R, Tomaselli F, Delia G, Tambasco D

Aesthetic plastic surgery2 Jul 2025Cited by 10 (Europe PMC)

PMID40603775 (opens in a new tab)DOI10.1007/s00266-025-05015-3 (opens in a new tab)PepBankPUB-40603775
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanObservational studySafety outcome

    In patients undergoing 360-degree lipoabdominoplasty, semaglutide-treated patients had no significant difference in major postoperative complications compared with a retrospective control group.

    In plain wordsIn patients having lipoabdominoplasty, major complications after surgery did not differ significantly between semaglutide-treated patients and controls.

    Peptide
    Semaglutide
    Outcome
    No significant changeMajor postoperative complications
    Study

    n: not reported in source

    Comparator
    Retrospective control group (no GLP-1 treatment)
    Outcome group
    Adverse events · Skin and wound
    Studied dose
    Dose not stated

    Source sentences

    Summary
    No statistically significant differences were observed in major postoperative complications between the two groups.
    1 context sentence
    Summary · context
    A prospective cohort of 21 patients treated with semaglutide (Group G1) was compared with a retrospectively selected control group (Group G2).
  2. 02HumanObservational studySafety outcome

    In patients undergoing 360-degree lipoabdominoplasty, hyperpigmentation was more frequent in the semaglutide group than in controls, but not significantly (p = 0.10).

    In plain wordsIn patients having lipoabdominoplasty, skin darkening was more common with semaglutide than in controls, but the difference was not statistically significant.

    Peptide
    Semaglutide
    Outcome
    No significant changeHyperpigmentation after surgery
    Study

    n: not reported in source

    Comparator
    Retrospective control group (no GLP-1 treatment)
    Outcome group
    Adverse events · Skin and wound
    Studied dose
    Dose not stated

    Source sentences

    Summary
    However, hyperpigmentation and bruising were more frequent in the GLP-1 treated group (p = 0.10 and p = 0.09, respectively), suggesting a potential metabolic or vascular effect of the drug.
    1 context sentence
    Summary · context
    A prospective cohort of 21 patients treated with semaglutide (Group G1) was compared with a retrospectively selected control group (Group G2).
  3. 03HumanObservational studySafety outcome

    In patients undergoing 360-degree lipoabdominoplasty, bruising was more frequent in the semaglutide group than in controls, but not significantly (p = 0.09).

    In plain wordsIn patients having lipoabdominoplasty, bruising was more common with semaglutide than in controls, but the difference was not statistically significant.

    Peptide
    Semaglutide
    Outcome
    No significant changeBruising after surgery
    Study

    n: not reported in source

    Comparator
    Retrospective control group (no GLP-1 treatment)
    Outcome group
    Adverse events · Skin and wound
    Studied dose
    Dose not stated

    Source sentences

    Summary
    However, hyperpigmentation and bruising were more frequent in the GLP-1 treated group (p = 0.10 and p = 0.09, respectively), suggesting a potential metabolic or vascular effect of the drug.
    1 context sentence
    Summary · context
    A prospective cohort of 21 patients treated with semaglutide (Group G1) was compared with a retrospectively selected control group (Group G2).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.